123 related articles for article (PubMed ID: 12412532)
1. New drug approved for colorectal cancer.
FDA Consum; 2002; 36(5):2. PubMed ID: 12412532
[No Abstract] [Full Text] [Related]
2. Oxaliplatin in colorectal cancer: an overview.
Armand JP; Boige V; Raymond E; Fizazi K; Faivre S; Ducreux M
Semin Oncol; 2000 Oct; 27(5 Suppl 10):96-104. PubMed ID: 11049040
[No Abstract] [Full Text] [Related]
3. A speedy approval.
Schultz S
US News World Rep; 2002 Aug 26-Sep 2; 133(8):26. PubMed ID: 12219556
[No Abstract] [Full Text] [Related]
4. Oxaliplatin-based chemotherapy in the management of colorectal cancer.
Capdevila J; Elez E; Peralta S; Macarulla T; Ramos FJ; Tabernero J
Expert Rev Anticancer Ther; 2008 Aug; 8(8):1223-36. PubMed ID: 18699761
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin (Eloxatin) for advanced colon cancer.
Med Lett Drugs Ther; 2003 Jan; 45(1148):7-8. PubMed ID: 12571541
[No Abstract] [Full Text] [Related]
6. Oxaliplatin: a novel platinum analog with activity in colorectal cancer.
Berg D
Oncol Nurs Forum; 2003; 30(6):957-66. PubMed ID: 14603353
[TBL] [Abstract][Full Text] [Related]
7. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
Oncology (Williston Park); 2012 Oct; 26(10):896. PubMed ID: 23175993
[No Abstract] [Full Text] [Related]
8. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.
Kopetz S; Overman M; Chang DZ; Glover KY; Shureiqi I; Wolff RA; Abbruzzese JL; Eng C
J Clin Oncol; 2008 Apr; 26(12):2000-5. PubMed ID: 18421052
[TBL] [Abstract][Full Text] [Related]
9. Molecule of the month. Vorinostat.
Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
[No Abstract] [Full Text] [Related]
10. From the Food and Drug Administration.
Crawford LM
JAMA; 2002 Sep; 288(10):1225. PubMed ID: 12215114
[No Abstract] [Full Text] [Related]
11. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
Oestreicher P
ONS Connect; 2007; 22(8 Suppl):37-8. PubMed ID: 17824557
[No Abstract] [Full Text] [Related]
12. A historical perspective on oxaliplatin: rethinking the role of platinum compounds and learning from near misses.
Cvitkovic E
Semin Oncol; 1998 Apr; 25(2 Suppl 5):1-3. PubMed ID: 9609102
[No Abstract] [Full Text] [Related]
13. [Gleaning from the American Oncology Congress. A new standard in colorectal carcinoma].
MMW Fortschr Med; 2002 Oct; 144(41):61. PubMed ID: 12474374
[No Abstract] [Full Text] [Related]
14. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
15. OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy.
Rosa DD; Ismael GF; de Azambuja E; Braga S; Cardoso F; Bleiberg H
J Clin Oncol; 2006 Nov; 24(32):5176-7; author reply 5177. PubMed ID: 17093286
[No Abstract] [Full Text] [Related]
16. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
[TBL] [Abstract][Full Text] [Related]
17. Dual-action drug approved for use in advanced breast cancer.
McBride D
ONS Connect; 2007 Jun; 22(6):19. PubMed ID: 17598617
[No Abstract] [Full Text] [Related]
18. Oxaliplatin.
Graham J; Mushin M; Kirkpatrick P
Nat Rev Drug Discov; 2004 Jan; 3(1):11-2. PubMed ID: 14756144
[No Abstract] [Full Text] [Related]
19. Hepatocellular carcinoma and nodular regenerative hyperplasia after chemotherapy for metastatic colorectal carcinoma.
Calderaro J; Azoulay D; Zafrani ES
Hepatology; 2014 Oct; 60(4):1440-1. PubMed ID: 24604623
[No Abstract] [Full Text] [Related]
20. [Colorectal carcinoma--approval of eloxatine in adjuvant therapy--better chances for recovery].
Krankenpfl J; 2004; 42(7-10):234. PubMed ID: 15675396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
